文献速递血栓与止血

晚期预防治疗对血友病关节状态的影响:一项随机试验

Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
PubMed 文献 · J Thromb Haemost · 2017-10-10

SPINART 是一项为期 3 年的开放标签随机跨国试验,纳入 12–50 岁伴关节病变的重型血友病 A 男性,比较蔗糖配方重组凝血因子 VIII 预防治疗与按需治疗。预防治疗组出血事件减少 94%,关节健康、生活质量、疼痛、活动、满意度及医疗资源利用均优于按需治疗,但 MRI 关节结构评分变化两组无差异。

要点

  • 预防治疗组出血事件较按需治疗减少 94%,35.7% 无出血、76.2% 年出血少于 2 次。
  • 预防治疗改善 CAJAS 关节健康评分与 HAEMO-QoL-A 生活质量评分,并减少慢性疼痛约 50%。
  • 两组 MRI 关节结构评分变化无差异,提示已存在的关节病变可能不可逆。

核心结论

  • 在伴关节病变的重型血友病 A 成人中,为期 3 年的预防治疗较按需治疗减少出血、疼痛和医疗资源利用,改善关节健康、活动、满意度和健康相关生活质量,但未减少结构性关节病变进展,提示已存在的关节病变可能不可逆。

研究设计与样本

  • SPINART 为开放标签、随机、跨国研究,纳入 12–50 岁重型血友病 A 男性,要求凝血因子 VIII 暴露日 ≥150、无抑制物、过去 5 年无连续超过 12 个月的预防治疗,随机接受蔗糖配方重组凝血因子 VIII 预防治疗或按需治疗。

主要发现

  • 预防治疗 3 年后依从性良好,出血事件减少 94%,35.7% 的预防治疗参与者无出血,76.2% 年出血少于 2 次。
  • CAJAS 评分最小二乘均值预防治疗组为 -0.31(n=42),按需治疗组为 +0.63(n=42)。
  • HAEMO-QoL-A 评分最小二乘均值预防治疗组为 +3.98(n=41),按需治疗组为 -6.00(n=42)。
  • 预防治疗组慢性疼痛减少 50%,医疗资源利用约减少两倍;活动、EQ-5D-3L 评分和满意度评分也倾向于预防治疗。
  • MRI 评分变化预防治疗组最小二乘均值为 +0.79(n=41),按需治疗组为 +0.96(n=38),两组无差异。

临床怎么用

  • 作者认为,预防治疗改善功能,但必须在关节出血发生前开始才能预防关节病变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3-year randomized clinical trial of late/tertiary prophylaxis vs on-demand therapy. Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Prophylaxis improves function but must start before joint bleeding onset to prevent arthropathy. SUMMARY: Background Limited data exist on the impact of prophylaxis on adults with severe hemophilia A and pre-existing joint disease. Objectives To describe 3-year bleeding, joint health and structure, health-related quality-of-life (HRQoL) and other outcomes from the open-label, randomized, multinational SPINART study. Patients/Methods Males aged 12-50 years with severe hemophilia A, ≥ 150 factor VIII exposure days, no inhibitors and no prophylaxis for > 12 consecutive months in the past 5 years were randomized to sucrose-formulated recombinant FVIII prophylaxis or on-demand therapy (OD). Data collected included total and joint bleeding events (BEs), joint structure (magnetic resonance imaging [MRI]), joint health (Colorado Adult Joint Assessment Scale [CAJAS]), HRQoL, pain, healthcare resource utilization (HRU), activity, and treatment satisfaction. Results Following 3 years of prophylaxis, adults maintained excellent adherence, with a 94% reduction in BEs despite severe pre-existing arthropathy; 35.7% and 76.2% of prophylaxis participants were bleed-free or had fewer than two BEs per year, respectively. As compared with OD, prophylaxis was associated with improved CAJAS scores (least squares [LS] mean, - 0.31 [n = 42] versus + 0.63 [n = 42]) and HAEMO-QoL-A scores (LS mean, + 3.98 [n = 41] versus - 6.00 [n = 42]), less chronic pain (50% decrease), and approximately two-fold less HRU; activity, Euro QoL-5D-3L (EQ-5D-3L) scores and satisfaction scores also favored prophylaxis. However, MRI score changes were not different for prophylaxis versus OD (LS mean, + 0.79 [n = 41] versus + 0.96 [n = 38]). Conclusions Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that pre-existing joint arthropathy may be irreversible.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017. PMID: 28836341. doi:10.1111/jth.13811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。